Suppr超能文献

硝苯地平添加至冠状动脉疾病的最大剂量硝酸盐和β-肾上腺素能受体阻滞剂治疗方案中。

Addition of nifedipine to maximal nitrate and beta-adrenoreceptor blocker therapy in coronary artery disease.

作者信息

White H D, Polak J F, Wynne J, Holman B L, Antman E M, Nesto R W

出版信息

Am J Cardiol. 1985 May 1;55(11):1303-7. doi: 10.1016/0002-9149(85)90493-x.

Abstract

The effects of oral nifedipine on left ventricular (LV) diastolic function were assessed in 14 patients with coronary artery disease (CAD) who had symptoms despite therapy with beta-adrenoceptor blocking drugs and nitrates. Rest and exercise gated radionuclide ventriculography was performed before and a mean of 13 days after the addition of oral nifedipine (80 to 120 mg/day) to baseline medication. Ejection fraction did not increase in any patient during exercise. The addition of nifedipine slightly improved the LV ejection fraction response to exercise (control, 49 +/- 8% rest vs 44 +/- 9% exercise; nifedipine, 47 +/- 6% vs 48 +/- 8%). With nifedipine treatment, diastolic function improved, with a decrease in the time to peak filling rate (PFR) at rest (from 174 +/- 34 to 152 +/- 31 ms, p less than 0.005) and an increase in PFR with exercise (from 2.5 +/- 0.6 to 3.4 +/- 0.7 end-diastolic volume/s, p less than 0.0005). Using the ratio of PFR/peak ejection rate as a variable, preferential improvement of diastolic over systolic function occurred during exercise (1.03 +/- 0.29 baseline vs 1.4 +/- 0.43 with nifedipine, p less than 0.01). Duration of exercise increased by a mean of 21% with nifedipine (from 454 +/- 150 to 550 +/- 159 seconds, p less than 0.005); all 14 patients were limited by angina pectoris at baseline, whereas only 5 patients were limited by angina pectoris after nifedipine treatment. This study shows that global LV diastolic function is improved by oral nifedipine treatment both at rest and during exercise in patients on maximally tolerated doses of beta-adrenoreceptor blockers and nitrates, and is associated with improvement of symptoms and exercise tolerances.

摘要

在14例尽管接受了β-肾上腺素能受体阻滞剂和硝酸盐治疗仍有症状的冠心病(CAD)患者中,评估了口服硝苯地平对左心室(LV)舒张功能的影响。在将口服硝苯地平(80至120mg/天)添加到基线药物治疗之前以及平均13天后,分别进行了静息和运动门控放射性核素心室造影。运动期间,没有患者的射血分数增加。添加硝苯地平后,LV射血分数对运动的反应略有改善(对照组,静息时为49±8%,运动时为44±9%;硝苯地平组,静息时为47±6%,运动时为48±8%)。接受硝苯地平治疗后,舒张功能得到改善,静息时达到峰值充盈率(PFR)的时间缩短(从174±34毫秒降至152±31毫秒,p<0.005),运动时PFR增加(从2.5±0.6增加至3.4±0.7舒张末期容积/秒,p<0.0005)。以PFR/峰值射血率的比值作为变量,运动期间舒张功能比收缩功能优先得到改善(基线时为1.03±0.29,硝苯地平治疗后为1.4±0.43,p<0.01)。硝苯地平治疗后,运动持续时间平均增加了21%(从454±150秒增至550±159秒,p<0.005);所有14例患者在基线时均受心绞痛限制,而硝苯地平治疗后只有5例患者受心绞痛限制。本研究表明,在接受最大耐受剂量β-肾上腺素能受体阻滞剂和硝酸盐治疗的患者中,口服硝苯地平治疗可在静息和运动时改善整体LV舒张功能,并与症状改善和运动耐量提高相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验